ArticleFEBS open bio2025
RETRACTION: SPC25 May Promote Proliferation and Metastasis of Hepatocellular Carcinoma via p53.
Article in FEBS open bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Retraction of
Authors and funding
0 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
retractionF. Chen, K. Zhang, Y. Huang, F. Luo, K. Hu, and Q. Cai, "SPC25 May Promote Proliferation and Metastasis of Hepatocellular Carcinoma via p53," FEBS Open Bio 10, no. 7 (2020): 1261-1275. https://doi.org/10.1002/2211-5463.12872. The above article, published online on 29 April 2020 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the journal Editor-in-Chief, Miguel De la Rosa; the Federation of European Biochemical Societies; and John Wiley & Sons Ltd., UK. A third party reported that images in Figures 11A, 11B, and 11C had been published in other articles both prior to and after the publication of this article and are also listed as representing different experiments [Ling et al. 2019 (https://doi.org/10.3892/ijo.2019.4926)]; [Ke et al. 2020 (https://doi.org/10.1186/s12935-020-01474-7)]; and [Ling et al. 2021 (https://doi.org/10.18632/aging.203318)]. Additionally, the Migration and Invasion images for si-SPC25 contain an overlapping section. An investigation by the journal confirmed these instances of image duplication and also discovered that the HepG2 and SMMC-7721 cell lines discussed in this article are known to be misclassified and contaminated, respectively. The authors did not respond to an inquiry and request for original data by the publisher. The retraction has been agreed to because the evidence of image duplication across multiple publications, in which the images are reported as different samples by different author groups, fundamentally compromises the editors' confidence in the results presented. As a result, the Editor-in-Chief, FEBS Press, and John Wiley and Sons Ltd. have determined that a retraction is necessary. The authors did not respond to our notice regarding the retraction.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.